The Department of Infectious Diseases at Augusta University conducts Clinical Trials
relating to a wide variety of pertinent infectious diseases. The following is a non-comprehensive
list of currently active studies in the department. If you are interested in learning
more about a specific study, please contact the study coordinator listed for the study and we would be more than happy to provide
you will further details.
|
ClinicalTrials.gov#
|
Official Title
|
Primary Investigator
|
Study Coordinator
|
Sponsor
|
NCT04426695
|
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S)
SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19 |
Jose Vazquez |
Aprile Osborn |
Regeneron Pharmaceuticals |
ANCT04439071
|
Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19
(FITE19) |
Jose Vazquez |
Aprile Osborn |
PTC Therapeutics |
NCT03667690
|
A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety
of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Optional Oral
Fluconazole Step-down in the Treatment of Subjects with Candidemia and/or Invasive
Candidasis (RESTORE) |
Jose Vazquez |
Aprile Osborn |
Cidara Therapeutics |
| NCT04340388 |
Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular
Disease in Persons Living With HIV |
Jonell Poe |
Ryan Harris
Amber Ladak
Reva Crandall
Jacob Looney
|
None |
NCT04633187
|
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects
of EDP-938 in Adult Hematopoietic Cell Transplant Recipients With Acute Respiratory
Syncytial Virus Infection of the Upper Respiratory Tract |
Andrew Chao |
Aprile Osborn |
Enanta Pharmceuticals |
| NCT04442737 |
A Phase 4, Randomized, Active-Controlled, Open-label Study to Evaluate the Safety
and Tolerability of Switching to Once-Daily Darunavir/Cobicistat/Emtricitabine/Tenofovir
Alafenamide (D/C/F/TAF) Fixed-dose Combination (FDC) Regimen in Virologically-suppressed
Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Experiencing Rapid
Weight Gain With an INI + TAF/FTC ARV Regimen |
Cheryl Newman |
Marti Farrough |
Janssen Scientific Affairs |
| NCT03059992 |
Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in
Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal
Treatment (FURI) |
Jose Vazquez |
Aprile Osborn |
|
| |
SARS CoV-2 shedding, sequence variation and immune responses in confirmed and suspected
COVID-19 patients |
Jose Vazquez |
Aprile Osborn |
|
| NCT04160468 |
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of
a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for
the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Including
Right-Sided Infective Endocarditis (DISRUPT) |
Jose Vazquez |
Aprile Osborn |
|
